Serum Anti-müllerian hormone, follicle stimulating hormone and antral follicle count measurement cannot predict pregnancy rates in IVF/ICSI cycles

  • Sezai Sahmay
  • Gökhan Demirayak
  • Onur Guralp
  • Pelin Ocal
  • Levent M. Senturk
  • Engin Oral
  • Tulay Irez



To investigate whether serum anti-müllerian hormone (AMH), follicle stimulating hormone (FSH), or antral follicle count (AFC) are predictive for clinical pregnancy in in vitro fertilization (IVF) patients.


Serum AMH, inhibin B, FSH, luteinizing hormone (LH), estradiol (E2), prolactin, and thyroid stimulating hormone (TSH) levels and AFC of 189 women under 40 years of age were investigated. Pregnant and non-pregnant women were compared.


Forty-seven (24.8 %) clinical pregnancies were observed in 189 women. There was no significant difference in terms of mean age, duration of infertility, body mass index, AMH, LH, FSH, E2, TSH, Inhibin B, AFC and total oocyte number between women who did and who did not become pregnant. Additionally, there was no significant difference in clinical pregnancy rates between the quartiles of AMH, FSH and AFC. (P values were 0.668, 0.071, and 0.252, respectively.)


Serum AMH and FSH, and AFC cannot predict clinical pregnancy in IVF patients under 40; the pregnancy rate tends to increase as AMH increases, although this remains non-significant.


Antimüllerian hormone Follicle stimulating hormone Antral follicle count Clinical pregnancy rate 


  1. 1.
    Majumder K, Gelbaya TA, Laing I, Nardo LG. The use of anti-Müllerian hormone and antral follicle count to predict the potential of oocytes and embryos. Eur J Obstet Gynecol Reprod Biol. 2010;150(2):166–70.PubMedCrossRefGoogle Scholar
  2. 2.
    Borini A, Dal Prato L. (2005) Tailoring FSH and LH administration to individual patients. Reprod Biomed Online.;11:283–93.PubMedCrossRefGoogle Scholar
  3. 3.
    Check JH, Peymer M, Lurie D. (1998) Effect of age on pregnancy outcome without assisted reproductive technology in women with elevated early follicular phase serum follicle-stimulating hormone levels. Gynecologic and Obstetric Investigation, 45, 217–220.PubMedCrossRefGoogle Scholar
  4. 4.
    Faddy MJ, Gosden RG. (1995) A mathematical model of follicle dynamics in the human ovary. Human Reproduction,10, 770–775.PubMedGoogle Scholar
  5. 5.
    Scott RT, Toner JP, Muasher SJ Oehninger S, Robinson S, Rosenwaks Z.(1989) Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertility and Sterility, 51, 651–654.PubMedGoogle Scholar
  6. 6.
    Toner JP, Philput CB, Jones GS, Muasher SJ. (1991) Basal follicle-stimulating hormone level is a better predictor of in vitro fertilization performance than age. Fertility and Sterility, 55, 784–791.PubMedGoogle Scholar
  7. 7.
    Seifer DB, Lambert-Messerlian G, Hogan J, Gardiner AC, Blazar AS, Berk CA. (1997) Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertility and Sterility, 67, 110–114PubMedCrossRefGoogle Scholar
  8. 8.
    Lekamge DN, Barry M, Kolo M, Lane M, Gilchrist RB, Tremellen KP. (2007) Anti-Müllerian hormone as a predictor of IVF outcome. Reprod Biomed Online.;14(5):602–10PubMedCrossRefGoogle Scholar
  9. 9.
    Josso N. (2008) Professor Alfred Jost: the builder of modern sex differentiation. Sex Dev.;2(2):55–63. Epub 2008 Jun 20.Google Scholar
  10. 10.
    Durlinger AL, Visser JA, Themmen AP. (2002) Regulation of ovarian function: The role of anti-müllerian hormone. Reproduction.;124:601–9PubMedCrossRefGoogle Scholar
  11. 11.
    La Marca A, Broekmans FJ, Volpe A, Fauser BC, Macklon N. (2009), ESHRE Special Interest Group for Reproductive Endocrinology–AMH Round Table: Anti-Mullerian hormone (AMH): what do we still need to know? Hum Reprod, 24:2264–2275.PubMedCrossRefGoogle Scholar
  12. 12.
    Durlinger ALL, Gruijters MJG, Kramer P, Karels B, Kumar TR, Matzuk MM, Rose UM, de Jong FH, Uilenbroek JT, Grootegoed JA, Themmen AP. (2001) Anti-mullerian hormone attenuates the effect of FSH on follicle development in the mouse ovary. Endocrinology;142:4891–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Weenen C, Laven JSE, von Bergh ARM, Cranfield M, Groome NP, Visser JA, Kramer P, Fauser BC, Themmen AP. (2004) Anti-mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod;10:77–83.PubMedCrossRefGoogle Scholar
  14. 14.
    Baarends WM, Uilenbroek JT, Kramer P, Hoogerbrugge JW, van Leeuwen EC, Themmen AP, Grootegoed JA. (1995) Anti-mullerian hormone and anti-mullerian hormone type 2 receptor messenger ribonucleic acid expressions in rat ovaries during postnatal development, the estrous cycle and gonadotropin-induced follicle growth. Endocrinology;136:4951–62.PubMedCrossRefGoogle Scholar
  15. 15.
    Sahmay S, Guralp O, Senturk LM, Imamoglu M, Kucuk M, Irez T. Serum anti-mullerian hormone concentrations in reproductive age women with and without polycystic ovary syndrome: the influence of body mass index. Japan Society for Reproductive Medicine. 2011.Google Scholar
  16. 16.
    Ebner T, Sommergruber M, Moser M, Shebl O, Schreier-Lechner E, Tews G. (2006) Basal level of anti-mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod;21:2022–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Fong SL, Baart EB, Martini E Schipper I, Visser JA, Themmen AP, de Jong FH, Fauser BJ, Laven JS. (2008) Anti-mullerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality. Reprod Biomed Online;16: 664–70.CrossRefGoogle Scholar
  18. 18.
    Irez T, Ocal P, Guralp O, Cetin M, Aydogan B, Sahmay S. Different serum anti-Müllerian hormone concentrations are associated with oocyte quality, embryo development parameters and IVF-ICSI outcomes. Arch Gynecol Obstet. 2011;284(5):1295–301.Google Scholar
  19. 19.
    Eldar-Geva T, Ben-Chetrit A, Spitz IM, Rabinowitz R, Markowitz E, Mimoni T, Gal M, Zylber-Haran E, Margalioth EJ. (2005) Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Hum Reprod.;20(11):3178–83.PubMedCrossRefGoogle Scholar
  20. 20.
    Elgindy EA, El-Haieg DO, El-Sebaey A. (2008) Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients. Fertil Steril.;89(6):1670–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. (2004) Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril.;82(5):1323–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Nelson SM, Yates RW, Fleming R. (2007) Serum anti-mullerian hormone and FSH: Prediction of live birth and extremes of response in stimulated cycles–implications for individualization of therapy. Hum Reprod;22:2414–21.PubMedCrossRefGoogle Scholar
  23. 23.
    Wu CH, Chen YC, Wu HH, Yang JG, Chang YJ, Tsai HD. (2009) Serum anti-Müllerian hormone predicts ovarian response and cycle outcome in IVF patients. J Assist Reprod Genet.; 26(7):383–9.Google Scholar
  24. 24.
    Deffieux X, Antoinne JM. (2003) Inhibins, activins and anti-Müllerian hormone: structure, signalling pathways, roles and predictive value in reproductive medicine. Gynecol Obstet Fertil;31(11):900–11PubMedCrossRefGoogle Scholar
  25. 25.
    Penarrubia J, Fabregues F, Manau D, Creus M, Casals G, Casamitjana R, Carmona F, Vanrell JA, Balasch J. (2005) Basal and stimulation day 5 anti- Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist-gonadotropin treatment. Hum Reprod;20:915–22.PubMedCrossRefGoogle Scholar
  26. 26.
    Smeenk JMJ, Sweep FCGJ, Zielhuis GA, Kremer JAM, Thomas CMG, Braat DDM. (2007) Anti-mullerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracytoplasmic sperm injection. Fertil Steril;1:223–6.CrossRefGoogle Scholar
  27. 27.
    Tremellen K, Kolo M. (2010) Serum anti-Mullerian hormone is a useful measure of quantitative ovarian reserve but does not predict the chances of live-birth pregnancy. Aust N Z J Obstet Gynaecol.;50(6):568–72.PubMedCrossRefGoogle Scholar
  28. 28.
    Fanchin R, Schonauer LM, Righini C, Guibourdenche J, Frydman R, Taieb J. (2003) Serum anti mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod;18:323–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Takahashi C, Fujito A, Kazuka M, Sugiyama R, Ito H, Isaka K. (2008) Anti-Müllerian hormone substance from follicular fluid is positively associated with success in oocyte fertilization during in vitro fertilization. Fertil Steril.;89(3):586–91.PubMedCrossRefGoogle Scholar
  30. 30.
    Wunder DM, Guibourdenche J, Birkhäuser MH, Bersinger NA. (2008) Anti-Müllerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril.;90(6):2203–10.PubMedCrossRefGoogle Scholar
  31. 31.
    Broer SL, Mol BW, Hendriks D, Broekmans FJ. (2009) The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril.;91(3):705–14.PubMedCrossRefGoogle Scholar
  32. 32.
    Sahmay S, Cetin M, Ocal P, Kaleli S, Senol H, Birol F, Irez T. Serum anti-Müllerian hormone level as a predictor of poor ovarian response in IVF patients. Reprod Med Biol. 2011;10:9–14.CrossRefGoogle Scholar
  33. 33.
    Ocal P, Sahmay S, Cetin M, Irez T, Guralp O, Cepni I. Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles. J Assist Reprod Genet. 2011;28(12):1197–203.PubMedCrossRefGoogle Scholar
  34. 34.
    Wang JG, Douglas NC, Nakhuda GS, Choi JM, Park SJ, Thornton MH, Guarnaccia MM, Sauer MV. The association between anti-Müllerian hormone and IVF pregnancy outcomes is influenced by age. Reprod Biomed Online. 2010 Dec;21(6):757–61.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Sezai Sahmay
    • 1
  • Gökhan Demirayak
    • 2
  • Onur Guralp
    • 2
  • Pelin Ocal
    • 1
    • 4
  • Levent M. Senturk
    • 1
  • Engin Oral
    • 1
  • Tulay Irez
    • 3
  1. 1.Department of Obstetrics and Gynecology, Division of Reproductive EndocrinologyIstanbul University, Cerrahpasa School of MedicineIstanbulTurkey
  2. 2.Department of Obstetrics and GynecologyIstanbul University, Cerrahpasa School of MedicineIstanbulTurkey
  3. 3.Department of Obstetrics and Gynecology, Division of EmbryologyIstanbul University, Cerrahpasa School of MedicineIstanbulTurkey
  4. 4.Istanbul Universitesi, Cerrahpasa Tip FakultesiIstanbulTurkey

Personalised recommendations